Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma

DSpace Repository

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma

Author: Chesney, Jason; Puzanov, Igor; Collichio, Frances; Singh, Parminder; Milhem, Mohammed M.; Glaspy, John; Hamid, Omid; Ross, Merrick; Friedlander, Philip; Garbe, Claus; Logan, Theodore F.; Hauschild, Axel; Lebbe, Celeste; Chen, Lisa; Kim, Jenny J.; Gansert, Jennifer; Andtbacka, Robert H. I.; Kaufman, Howard L.
Tübinger Autor(en):
Garbe, Claus
Published in: Journal of Clinical Oncology (2018), Bd. 36, H. 17, S. 1658-1667
Verlagsangabe: Amer Soc Clinical Oncology
Language: English
Full text: http://dx.doi.org/10.1200/JCO.2017.73.7379
ISSN: 1527-7755
DDC Classifikation: 610 - Medicine and health
Dokumentart: Article
Show full item record

This item appears in the following Collection(s)